| Literature DB >> 35397581 |
Yun-Qiu Zhao1, Yong-Jun Liu1, Wei-Ting Ji1, Kun Liu1, Bei Gao1, Xin-Yi Tao1, Ming Zhao2, Feng-Qing Wang3, Dong-Zhi Wei1.
Abstract
BACKGROUND: 7β-hydroxylated steroids (7β-OHSt) possess significant activities in anti-inflammatory and neuroprotection, and some of them have been widely used in clinics. However, the production of 7β-OHSt is still a challenge due to the lack of cheap 7β-hydroxy precursor and the difficulty in regio- and stereo-selectively hydroxylation at the inert C7 site of steroids in industry. The conversion of phytosterols by Mycolicibacterium species to the commercial precursor, androst-4-ene-3,17-dione (AD), is one of the basic ways to produce different steroids. This study presents a way to produce a basic 7β-hydroxy precursor, 7β-hydroxyandrost-4-ene-3,17-dione (7β-OH-AD) in Mycolicibacterium, for 7β-OHSt synthesis.Entities:
Keywords: 7β-hydroxyandrost-4-ene-3,17-dione; Mycolicibacterium; Nicotinamide adenine dinucleotide phosphate regeneration; Phytosterols; mP450-BM3
Mesh:
Substances:
Year: 2022 PMID: 35397581 PMCID: PMC8994266 DOI: 10.1186/s12934-022-01786-5
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1The production of 7β-OH-AD by recombinant Mycolicibacterium neoaurum strains with the NADPH regeneration system
Strains and plasmids used in this study
| Name | Description | Sources |
|---|---|---|
| Strains | ||
| | Transgen Biotech | |
| | Source of G6PDH and NADK genes | This lab |
| M3 | This lab | |
| M3-261 | M3 containing pMV261 as control | This study |
| M3- | M3 expressing original P450-BM3 gene | This study |
| M3 | M3 expressing mP450-BM3 gene (F87A/T260G) | This study |
| M3 | M3 expressing mP450-BM3-0 gene (S72W/V78L/A82L | This study |
| /T88S/A328G/A330W) | ||
| M3 | M3 expressing mP450-BM3-0 and | This study |
| M3 | M3 expressing mP450-BM3-0 and | This study |
| M3 | M3 expressing mP450-BM3-0, | This study |
| Plasmids | ||
| pUC57- | The codon-optimized original P450-BM3 gene delivered | Shanghai Generay |
| by pUC57, AmpR | Biotech Co. Ltd | |
| pUC57- | The codon-optimized mP450-BM3 gene delivered by | Shanghai Generay |
| pUC57, AmpR | Biotech Co. Ltd | |
| pMV261 | Shuttle vector of | Dr. W. R. Jacobs Jr. for |
| providing pMV261 | ||
| pMV261 | pMV261 containing original P450-BM3 gene, KanR | This study |
| pMV261 | pMV261 containing mP450-BM3 gene, KanR | This study |
| pMV261 | pMV261 containing mP450-BM3-0 gene, KanR | This study |
| pMV261 | pMV261 containing NADK gene from | This study |
| pMV261 | pMV261 containing G6PDH gene from | This study |
| pMV261 | pMV261 containing mP450-BM3-0 gene and NADK2 | This study |
| Gene from | ||
| pMV261 | pMV261 containing mP450-BM3-0 gene and G6PDH2 | This study |
| Gene from | ||
| pMV261 | pMV261 containing mP450-BM3-0 gene, NADK2 and | This study |
| | G6PDH2 genes from |
AmpR: ampicillin-resistant, KanR: kanamycin-resistant
The specific activities of 7β-hydroxylase, NADK and G6PDH in recombinant Mycolicibacterium neoaurum strains
| Strains | Enzyme activity | ||
|---|---|---|---|
| 7β-hydroxylase | NADK | G6PDH | |
| (U g− 1) | (U g− 1) | (U g− 1) | |
| M3-261 | 0 | 1.24 ± 0.06 | 1.37 ± 0.07 |
| M3- | 0 | 1.17 ± 0.04 | 1.31 ± 0.12 |
| M3- | 1.42 ± 0.13 | 1.12 ± 0.07 | 1.25 ± 0.04 |
| M3- | 2.34 ± 0.11 | 1.08 ± 0.09 | 1.18 ± 0.05 |
| M3- | 2.57 ± 0.08 | 2.56 ± 0.12 | 1.21 ± 0.15 |
| M3- | 2.72 ± 0.12 | 1.24 ± 0.05 | 3.42 ± 0.13 |
| M3- | 3.03 ± 0.06 | 2.35 ± 0.15 | 3.34 ± 0.09 |
Fig. 2Rational design of the mP450-BM3 to improve its activity to AD. A Docking of the ligand AD into the mP450-BM3 crystal structure. AD is shown in green, heme is shown in red. B Relative activity of mP450-BM3 (WT) and mutants (away from the heme) to AD. C Relative activity of mP450-BM3 (WT) and mutants (close to the heme) to AD. D Relative activity of mP450-BM3 (WT) and the mutant (S72W/V78L/A82L/T88S/A328G/A330W) to AD. All assays were performed in triplicate with three independent measurements. Standard deviations of the biological replicates are represented by error bars
The durations and titer of PS conversion by different recombinant Mycolicibacterium neoaurum strains
| Strains | Durations (d) | Titer (mg L− 1) |
|---|---|---|
| M3-261 | – | 0 |
| M3- | – | 0 |
| M3- | 7 | 34.24 ± 1.34 |
| M3- | 7 | 66.25 ± 2.42 |
| M3- | 6 | 94.63 ± 2.27 |
| M3- | 6 | 117.46 ± 1.49 |
| M3- | 6 | 139.87 ± 3.73 |
Fig. 3The concentration and ratio of coenzymes in different recombinant Mycolicibacterium neoaurum strains. A The different coenzyme concentration on the 5th day in recombinant M. neoaurum strains. B The ratio of NAD+ to NADH in recombinant M. neoaurum strains. C The ratio of NADP+ to NADPH in recombinant M. neoaurum strains. D The ratio of NADH to NADPH in recombinant M. neoaurum strains. All assays were performed in triplicate with three independent measurements. Standard deviations of the biological replicates are represented by error bars
Fig. 4Growth and metabolism statues of different recombinant strains. A The growth (closed square) and phytosterols consumption (open square) of recombinant strains. B The glucose consumption of recombinant strains. All assays were performed in triplicate with three independent measurements. Standard deviations of the biological replicates are represented by error bars
Fig. 5The effect of different fermentation conditions on production of 7β-OH-AD. A Effects of different biomass of M3-mBM3-0-NADK2-G6PDH2 (6%, 9%, 12%, 15%) on 7β-OH-AD production. B Effects of different substrate concentrations (1 g L− 1, 3 g L− 1, 5 g L− 1, 7 g L− 1) on the conversion rate. C Effects of adding time of glucose (3 d, 4 d, 5 d, 6 d) on conversion rate. D Effects of concentrations of glucose supplement (10 g L− 1, 20 g L− 1, 30 g L− 1, 40 g L− 1) on conversion rate. All assays were performed in triplicate with three independent measurements. Standard deviations of the biological replicates are represented by error bars